source
- Cellectis abandons CAR-T programs, shifts focus to in vivo gene editingCellectis announced it will discontinue its donor-derived CAR‑T programs and redirect its efforts toward in vivo gene‑editing medicines. The company said the commercial and clinical landscape for…
- mRNA cancer vaccines’ biggest barriers to marketManufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.